Blue Trust Inc. Has $83,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Blue Trust Inc. grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 75.0% during the 4th quarter, HoldingsChannel reports. The firm owned 609 shares of the company’s stock after purchasing an additional 261 shares during the quarter. Blue Trust Inc.’s holdings in Neurocrine Biosciences were worth $83,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NBIX. Brooklyn Investment Group increased its position in shares of Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 115 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after acquiring an additional 309 shares in the last quarter. Truvestments Capital LLC acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth about $63,000. True Wealth Design LLC lifted its holdings in shares of Neurocrine Biosciences by 11,740.0% during the 3rd quarter. True Wealth Design LLC now owns 592 shares of the company’s stock valued at $68,000 after purchasing an additional 587 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Neurocrine Biosciences by 42.0% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock valued at $72,000 after purchasing an additional 157 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $122.62 on Friday. The firm has a 50-day moving average of $138.89 and a 200-day moving average of $131.77. The company has a market cap of $12.42 billion, a PE ratio of 32.87 and a beta of 0.33. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%. Analysts expect that Neurocrine Biosciences, Inc. will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the sale, the chief executive officer now owns 135,392 shares in the company, valued at $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kevin Charles Gorman sold 2,707 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.92, for a total value of $413,954.44. Following the transaction, the director now owns 517,030 shares in the company, valued at approximately $79,064,227.60. This trade represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 222,693 shares of company stock valued at $32,718,279. 4.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on NBIX. Canaccord Genuity Group dropped their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating on the stock in a report on Friday. Bank of America dropped their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a report on Friday. Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Barclays lifted their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 23rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $167.81.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.